Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00750867 · ClinicalTrials.gov registry record · Phase 2
Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
A Phase 2 study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00750867: Completed Phase 2 study, sponsored by University of Massachusetts, Worcester.
NCT00750867 is a Phase 2 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00750867, a Phase 2 study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
Multiple System Atrophy (MSA) is a progressive sporadic neurodegenerative disorder leading to widespread loss of brain cells that results in parkinsonian, cerebellar and autonomic dysfunction. The cause of the MSA remains unclear. Available treatment is symptomatic only and does not alter the course of disease. Although the cause of MSA remains unclear, there is evidence of presence of common neuroinflammatory mechanisms in the MSA brains including activation of microglia and production of toxic cytokines. This research protocol is based on hypothesis that the MSA progression can be altered by blocking the neuroinflammatory activity. This protocol includes administration of intravenous immunoglobulin (IVIg). IVIg contains antibodies derived from human plasma which can block the inflammatory responses in the brain that can lead to loss of brain cells.
Primary Outcome
The primary outcome measure was to evaluate the safety and tolerability of the IVIG infusions in patients with multiple system atrophy. The primary endpoint was defined as the frequency of adverse events (AE). AEs including their severity and relationship to the IVIG were assessed throughout the study and at least 60 days after the last infusion. The AEs were considered to be related to the IVIG infusion (infusional AE) if they occurred during an infusion or within 72 hours afterwards. Non-infus
Interventions
- DRUG intravenous immunoglobulin (IVIg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT00750867 record still lists
NCT00750867 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which intravenous immunoglobulin (IVIg) is the first listed.
NCT00750867 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00750867 about?
NCT00750867 is a clinical study titled "Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins". Multiple System Atrophy (MSA) is a progressive sporadic neurodegenerative disorder leading to widespread loss of brain cells that results in parkinsonian, cerebellar and autonomic dysfunction. The cause of the MSA remains unclear. Available treatment is symptomatic only and does not alter the course...
What is the current status of trial NCT00750867?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2008-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00750867?
The interventions under investigation include: intravenous immunoglobulin (IVIg) (DRUG).
Who is sponsoring clinical trial NCT00750867?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00750867's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia